- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
- 10-K Annual report
- 3.8 Certificate of Designation of Preferences
- 4.46 Common Stock Purchase Warrant
- 4.47 Common Stock Purchase Warrant
- 4.48 Common Stock Purchase Warrant
- 10.73 Agreement
- 10.74 Exchange Agreement
- 10.75 Exchange Agreement
- 10.76 Exchange Agreement
- 10.77 Exchange Agreement
- 10.78 Exchange Agreement
- 10.79 Exchange Agreement
- 10.80 Exchange Agreement
- 10.81 Exchange Agreement
- 10.82 Exchange Agreement
- 10.83 Exchange Agreement
- 10.84 Exchange Agreement
- 10.85 Exchange Agreement
- 10.86 Promissory Note
- 10.87 Exchange Agreement
- 10.88 Auctus Debt for Equity Exchange Agreement
- 23.1 Consent
- 31 Certification
- 32 Certification
- Download Excel data file
- View Excel data file
EXHIBIT 32
SECTION 1350 CERTIFICATION
In connection with the Annual Report of Guided Therapeutics, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Gene Cartwright, President, Chief Executive Officer and Acting Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
(1) | the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
(2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: | March 29, 2022 |
|
|
|
|
| /s/ Gene Cartwright |
|
Name: | Gene Cartwright |
|
Title: | President, Chief Executive Officer and Acting Chief Financial Officer |
|